search
Back to results

Young Adults With Early-onset Obesity Treated With Semaglutide (RESETTLE)

Primary Purpose

Obesity, Adolescent

Status
Recruiting
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
TCOC treatment
Semaglutide 3 mg
Sponsored by
Signe Torekov
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity, Adolescent focused on measuring GLP-1 RA, Semaglutide, Weight loss, Treatment resistant

Eligibility Criteria

18 Years - 28 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 18-28 years
  • The period from the initial treatment with TCOC protocol until inclusion in the study must be within 10 years.
  • Group A: BMI>30. Non-responders: No BMI SDS reduction (<0.1 BMI SDS) during TCOC protocol for more than one year and still have obesity (BMI>30).
  • Group B: BMI>30. Insufficient responders: BMI SDS reduction >0.25 BMI SDS during TCOC protocol for more than one year, but still have obesity (BMI>30).
  • Only baseline examination: Group C: BMI<30. Excellent responders: BMI SDS reduction >0.5 BMI SDS during TCOC protocol for more than one year and no longer have obesity (BMI<30).

Exclusion Criteria:

  • Participants diagnosed with known serious chronic illness including type 1 or 2 diabetes (or a randomly measured fasting plasma glucose > 7 mmol/l)
  • Angina pectoris, coronary heart disease, congestive heart failure (NYHA III-IV)
  • Severe renal impairment (creatinine clearance (GFR) <30 mL/min)
  • Severe hepatic impairment
  • Inflammatory bowel disease
  • Diabetic gastroparesis
  • Cancer
  • Chronic obstructive lung disease
  • Psychiatric disease, a history of major depressive or other severe psychiatric disorders
  • Use of medications causing clinically significant weight gain or loss
  • Previous bariatric surgery
  • A history of idiopathic acute pancreatitis
  • A family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma
  • Pregnancy, expecting pregnancy or breastfeeding. If a study participant is in doubt whether she could be pregnant, a urine pregnancy test is performed. Women with reproductive potential who are not using adequate contraceptive methods (combined oral contraceptive pill, progestin-only contraceptive pill, condoms, intrauterine device, injection, implant, or sterilization). Adequate contraception must be used throughout the study period and at least 2 months after discontinuation of trial medication (semaglutide will be present in the circulation for 5-7 weeks after the last dose).
  • Allergy to any of the ingredients/excipients of the study medication: Semaglutide, disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid, sodium hydroxide.

Sites / Locations

  • Holbæk University Hospital
  • University of Copenhagen, Department of Biomedical SciencesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Active Comparator

Placebo Comparator

Active Comparator

Placebo Comparator

No Intervention

Arm Label

Non-responders: TCOC+ semaglutide

Non-responders: TCOC+ placebo

Insufficient responders: TCOC+ semaglutide

Insufficient responders: TCOC+ placebo

Excellent Responders

Arm Description

Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).

Placebo: 2.4 mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).

Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).

Placebo: 2.4mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).

Outcomes

Primary Outcome Measures

Change in BMI (weight in kg/height in m^2) in non-responders
Weight will be measured to the nearest 0.1 kg. The same set of scales should ideally be used throughout the trial. Weight should be measured in a fasting state without shoes and wearing light indoor clothes. Height will be measured to the nearest 0.1 cm.

Secondary Outcome Measures

Change in body composition (fat mass and fat free mass) and body weight from before to after semaglutide treatment in non-responders to TCOC protocol compared to placebo
Body composition: Dual-energy X-ray absorptiometry scans will be performed in fasting state to measure body fat percentage (%).
Change in BMI (weight in kg/height in m^2), body composition (fat mass and fat free mass) and body weight from before to after semaglutide treatment in insufficient responders to TCOC protocol compared to placebo.
Dual-energy X-ray absorptiometry scans will be performed in fasting state to measure fat mass and lean mass (kg)
Compare BMI (weight in kg/height in m^2), body composition (fat mass and fat free mass) and body weight between excellent responders, non-responders and insufficient responders.
Dual-energy X-ray absorptiometry scans will be performed in fasting state to measure fat mass and lean mass (kg)

Full Information

First Posted
October 6, 2022
Last Updated
October 18, 2022
Sponsor
Signe Torekov
Collaborators
University of Leeds, Karolinska Institutet, Holbaek Sygehus, Rigshospitalet, Denmark
search

1. Study Identification

Unique Protocol Identification Number
NCT05574439
Brief Title
Young Adults With Early-onset Obesity Treated With Semaglutide
Acronym
RESETTLE
Official Title
Young Adults With Early-onset Obesity Treated With Semaglutide -The RESETTLE Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2022 (Actual)
Primary Completion Date
October 30, 2024 (Anticipated)
Study Completion Date
June 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Signe Torekov
Collaborators
University of Leeds, Karolinska Institutet, Holbaek Sygehus, Rigshospitalet, Denmark

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Introduction: The increasing prevalence of obesity is particularly pronounced among adolescents. Currently available treatment options consist of structured lifestyle interventions. However, 25 % of adolescents do not respond to lifestyle treatment, why new effective treatment strategies are needed. Therefore, the aim of this study is to investigate the effect of lifestyle interventions combined with the GLP-1 receptor agonist semaglutide to young adults with otherwise treatment resistant obesity. Methods and analysis: This is an investigator-initiated, randomized, placebo-controlled trial. 130-170 young adults (age 18-28) will be recruited from The Children's Obesity Clinic (TCOC), Department of Pediatrics, Holbæk Hospital. Based on their previous response to the TCOC protocol the participants will be divided in three groups: Group A: Non-responders: 55-75 young adults (BMI>30 kg/m2) who have not succeeded in losing weight during the structured lifestyle intervention (BMI SDS reduction <0.1) Group B: Insufficient responders: 55-75 young adults (BMI>30 kg/m2) who have succeeded in losing weight during the structured lifestyle intervention (BMI SDS reduction >0.25), but still have obesity. Group C: Excellent responders: 20 young adults, who have succeeded in losing weight during the structured lifestyle intervention (BMI SDS reduction >0.5) and no longer have obesity (BMI<30 kg/m2). Group A and B are randomized 2:1 to either semaglutide or placebo for 68 weeks. Group C will attend baseline examinations only and not undergo intervention. The primary endpoint is change in BMI from randomization to end-of-treatment. Ethics and dissemination: The trial has been approved by the Danish Medicines Agency (EudraCT 2019-002274-31) and by the ethical committee of the Capital Region of Denmark (H-20039422). The trial will be conducted in agreement with the Declaration of Helsinki and monitored to follow the guidelines for good clinical practice. Results will be submitted for publication in international peer-reviewed scientific journals.
Detailed Description
Background: The prevalence of obesity in adolescents has increased markedly in the past decades, thus entailing increased cumulative incidences of type 2 diabetes, cardiovascular disease, and chronic kidney disease (1). Adolescents with obesity are at a substantially elevated risk of developing morbid obesity and type 2 diabetes in early adulthood (2,3) and a recent large scale meta-analysis revealed that mortality increased approximately log-linearly with BMI over 25.0 kg/m² in all continents; and that this increment was greater in younger than older people (4). Furthermore, obesity increase the risk of stigmatization with respect to social relationships, entry into the job market, reduced self-esteem and other psychological problems (5). Thus, adolescents with obesity require particular medical attention. Since 2008, The Children's Obesity Clinic (TCOC), Department of Pediatrics, Copenhagen University Hospital Holbæk has treated more than 4000 children and adolescents with overweight or obesity using the TCOC protocol which includes regular counselling on diet, exercise, lifestyle and general health. The TCOC protocol has proven successful with a reduction in BMI standard deviation score (SDS) after 1.5 years of treatment obtained in 74% of the children and adolescents (6). In addition, significant improvements in lipid profile (7) the degree of hypertension (8), hepatic steatosis (9) and the presence of visceral fat (9) have been reported. However, approximately one in four of the children following the TCOC protocol do not achieve a reduction in BMI SDS. Furthermore, for the majority of children who reduce BMI SDS, obesity remains and represents a medical and personal issue. Lifestyle intervention is the method of choice for children with obesity, however, new effective treatment strategies for non-responders are urgently required. Glucagon-like peptide-1 (GLP-1) is secreted from endocrine cells in the intestine upon meal intake and reduces blood glucose and food intake in a dose-dependent manner (10-13). It has previously been shown that 1) people with obesity have impaired GLP-1 secretion already in the overweight state, indicating that low concentrations of GLP-1 may be part of obesity development (14), 2) weight loss induces a marked increase in GLP-1 response and this increase is part of a successfully maintained weight loss of >10 kg (15), 3) treatment with a GLP-1 receptor agonist (GLP-1 RA) facilitates long term weight loss maintenance (13 kg) accompanied by substantial improvement in metabolic health, compared to similar diet-induced weight loss maintenance (15-17),4) appetite sensation and eating behavior are important factors in maintenance of weight loss (18,19). Pathogenic mutations in the appetite-regulating melanocortin-4 receptor represent the most common cause of early-onset monogenic obesity that has been shown to be a type of obesity that is more resistant to lifestyle interventions (20) and even to bariatric surgery (21). Interestingly, this population is responsive to treatment with GLP-1 RA (liraglutide 3.0 mg daily) (22). This indicates that GLP-1 RA's can overrule lifestyle modification-resistant obesity due to the appetite-inhibiting effect. A new GLP1-1 RA (semaglutide) was approved by the European Medical Agency (EMA) for weight management in adults with obesity in January 2022. Placebo subtracted weight loss with semaglutide 2.4 mg was 13.9 % compared to 4.5% with liraglutide 3.0 mg after 68 weeks in adults with overweight or obesity (23). Thus, semaglutide has a potentially larger treatment effect also in young adults with childhood onset obesity. The treatment effect of semaglutide 2.4 mg in young adults with lifestyle-treatment-resistant childhood onset obesity is currently unknown, why the outcomes of this study is of high clinical and socioeconomic relevance. Study hypothesis: Treatment with a GLP-1 RA will facilitate weight loss in young adults with and without treatment-resistant childhood-onset obesity. Objectives: A) To treat young adults with obesity, who have been resistant to structured lifestyle intervention (TCOC protocol), with the GLP-1 RA, semaglutide 2.4 mg/ week. B) To treat young adults with obesity, who have responded with insufficient weight loss to the structured lifestyle intervention (TCOC protocol) and remain obese, with semaglutide 2.4 mg/ week. C) To identify underlying mechanisms of lifestyle-untreatable versus treatable childhood-onset obesity. Endpoints: Primary endpoint: 1. Change in BMI (weight in kg/height in m^2) from before to after semaglutide treatment in non-responders to TCOC protocol compared to placebo. Secondary endpoints: Change in body composition and body weight from before to after semaglutide treatment in non-responders to TCOC protocol compared to placebo Change in BMI (weight in kg/height in m^2), body composition and body weight from before to after semaglutide treatment in insufficient responders to TCOC protocol compared to placebo Compare BMI (weight in kg/height in m^2), body composition and body weight between excellent responders, non-responders and insufficient responders. Other prespecified endpoints: To determine the effect of GLP-1 RA treatment, and compare baseline data between the two intervention groups to excellent responders for the following outcomes: Circulating biomarkers of metabolic regulation to evaluate metabolic health (e.g. glucose and insulin for HOMA-IR and Matsuda index, HbA1c, lipids i.e. cholesterol, HDL, LDL, triglycerides, FFA and determination of glucose-tolerance status) will be measured. Furthermore, the investigator will measure blood pressure, pulse, and hip and waist circumference. Conventional Magnetic resonance imaging (MRI) and spectroscopy is used to assess effects on fat deposits in liver, viscera, and muscle. Site-specific bone- measurements, collection of bone markers (CTX and P1NP), and DEXA scans will be performed to assess bone-health. To explore the effects on appetite regulation and systemic markers of immuno- metabolism: Hormonal appetite regulation will be measured during meal tests and fasting (eg. GLP-1, Peptide YY, Glucagon, Leptin, Ghrelin, Liver-Expressed Antimicrobial Peptide 2 (LEAP2), Adiponectin) using our standard methodologies. In plasma samples various biomarkers of inflammation will be measured (eg sCD163, hsCRP, IL-1, IL- 1Rap IL-6, TNF-α, SAA1, SAA2, ORM1, ORM2) and oxidation (eg malonyldialdehyde, F2-Isoprostanes, etc.), IPS and metabolomics using plasma metabolomics and proteomics technique. To explore the effects on immuno-metabolic profile in human subcutaneous (sc) adipose tissue and gene expression profile of adipose tissue and in circulating inflammatory cells (PBMNCs). To explore the effect on food preferences and appetite sensation: Food preferences are assessed by a picture display test where standardized pictures of food items are shown Furthermore, the investigator will use eye tracking as well as galvanic skin response to record the participants' emotional response to the standardized food items using iMotion Software. Subjective appetite sensations will be obtained during a fixed standardized meal using electronic visual analogue scales (VAS) to record hunger, satiety, fullness, prospective food consumption, desire to eat something fatty, salty, sweet or savory, and palatability of the meals. To explore the effect on brain activation using magnetic resonance (MR) imaging: MR imaging of the brain will be conducted in a subset of participants by trained personnel at a registered clinical facility. An MRI scanner is composed of a long tube surrounded by a coil that forms a powerful magnetic field. Participants will be placed on an examination table in the centre of the tube in a supine position. By changing gradients in the magnetic field and transmitting radio waves, resonance of the atomic nuclei of the brain can be induced. During the scan the investigator will acquire both structural and functional information about the brain. The structural MRI sequences will provide a high-resolution anatomical image of the brain. A functional MRI (fMRI) scan provides the opportunity to track changes in e.g., blood oxygenation, which serve as an index for neural activation in different parts of the brain while the participants are at rest. This protocol includes morphological neuroimaging and resting-state fMRI. The MRI scanning session will last approximately one hour. To explore the genetic risk scores correlated to treatment response: All participants are chip genotyped to define polygenic risk scores. DNA material will be extracted from blood samples. The Infinium Global Screening Array will be used to analyze the array with Illumina Genome Studio before the bioinformatic removal of SNPs containing genes mentioned in the "American College Medical Genetics and Genomics" List. To explore the effect on the microbiota: The microbiome will be measured in fecal and saliva samples of participants. Furthermore, fecal and saliva samples were collected from the same individuals when they were children with obesity, allowing for comparison of potential differences already evident in childhood that may indicate later treatment response to lifestyle change and GLP-1RA treatment. To explore the effect on metabolomics in urine: Urine samples are collected at the two test days and will be stored frozen for later analyses for potential changes in the metabolomic profile.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Adolescent
Keywords
GLP-1 RA, Semaglutide, Weight loss, Treatment resistant

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Three groups will be identified based on their previous response to structured lifestyle interventions. Non-responders (group A) and insufficient responders (group B) are randomized 2:1 to either Semaglutide 2.4 mg/ week sc or placebo for 68 weeks. Group C (excellent responders) will attend baseline examinations only and not undergo intervention.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The above-mentioned are masked in terms of semaglutide/placebo. Statistical analysis of primary outcome will be blinded to the assessor.
Allocation
Randomized
Enrollment
170 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Non-responders: TCOC+ semaglutide
Arm Type
Active Comparator
Arm Description
Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
Arm Title
Non-responders: TCOC+ placebo
Arm Type
Placebo Comparator
Arm Description
Placebo: 2.4 mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
Arm Title
Insufficient responders: TCOC+ semaglutide
Arm Type
Active Comparator
Arm Description
Semaglutide: 2.4 mg/week SC, concentration: 3.0 mg/ml) in combination with TCOC treatment (i.e. diet/weight consultations).
Arm Title
Insufficient responders: TCOC+ placebo
Arm Type
Placebo Comparator
Arm Description
Placebo: 2.4mg/week SC in combination with TCOC treatment (i.e. diet/weight consultations).
Arm Title
Excellent Responders
Arm Type
No Intervention
Intervention Type
Behavioral
Intervention Name(s)
TCOC treatment
Intervention Description
The TCOC protocol is a chronic care, family-based and multidisciplinary childhood obesity treatment program involving behavior-changing techniques, based on current guidelines for best-practice and authoritative recommendations involving a multidisciplinary tertiary team of health care professionals.
Intervention Type
Drug
Intervention Name(s)
Semaglutide 3 mg
Intervention Description
Participants will be instructed to initiate at 0.24 mg SC once weekly for 4 weeks, and in 4 week intervals, increase the dose until a dose of 2.4 mg is reached. In case of prolonged side effects the dose may be adjusted to lower than 2.4mg/week.
Primary Outcome Measure Information:
Title
Change in BMI (weight in kg/height in m^2) in non-responders
Description
Weight will be measured to the nearest 0.1 kg. The same set of scales should ideally be used throughout the trial. Weight should be measured in a fasting state without shoes and wearing light indoor clothes. Height will be measured to the nearest 0.1 cm.
Time Frame
Change from baseline to end-of-treatment (68 weeks)
Secondary Outcome Measure Information:
Title
Change in body composition (fat mass and fat free mass) and body weight from before to after semaglutide treatment in non-responders to TCOC protocol compared to placebo
Description
Body composition: Dual-energy X-ray absorptiometry scans will be performed in fasting state to measure body fat percentage (%).
Time Frame
Change from baseline to end-of-treatment (68 weeks)
Title
Change in BMI (weight in kg/height in m^2), body composition (fat mass and fat free mass) and body weight from before to after semaglutide treatment in insufficient responders to TCOC protocol compared to placebo.
Description
Dual-energy X-ray absorptiometry scans will be performed in fasting state to measure fat mass and lean mass (kg)
Time Frame
Change from baseline to end-of-treatment (68 weeks)
Title
Compare BMI (weight in kg/height in m^2), body composition (fat mass and fat free mass) and body weight between excellent responders, non-responders and insufficient responders.
Description
Dual-energy X-ray absorptiometry scans will be performed in fasting state to measure fat mass and lean mass (kg)
Time Frame
Baseline comparison
Other Pre-specified Outcome Measures:
Title
HOMA-IR
Description
Fasting insulin (μU/mL) * fasting glucose (mmol/L) / 22.5
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Matsuda Index
Description
10000/sqrt(fasting glucose * fasting insulin * mean glucose * mean insulin)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Plasma Glucose
Description
mmol/L
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Plasma Insulin
Description
pmol/L
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
HbA1c
Description
mmol/mol
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Lipids
Description
Cholesterol (Total, HDL, LDL, VLDL) and triglycerides (TG)) (mmol/L)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Free Fatty Acids
Description
umol/L
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Waist and hip circumference
Description
Waist circumference, the midpoint between lowest rib and iliac crest, and hip circumference, the level of the great trochanters, will be measured in duplicate to the nearest 0.1 cm after gentle expiration.
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Blood pressure
Description
Blood pressure (systolic/diastolic) will be measured in duplicate from the non-dominant arm with a digital blood pressure monitor in sitting position after at least 5 min of rest (mmHg).
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Heart rate
Description
Heart rate (bpm)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Ectopic fat accumulation in liver, viscera and muscle
Description
Magnetic resonance imaging (MRI) and spectroscopy
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Neural activation in the resting state and in response to food-cues
Description
Structural and Functional Magnetic resonance imaging (MRI)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Bone mineral density
Description
Dual energy x-ray absorptiometry (DEXA) (g/cm^2)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Bone markers
Description
CTX (ng/l) and P1NP (µg/L)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Hormonal appetite regulation during meal tests and in fasting
Description
GLP-1, Peptide YY, Glucagon, Leptin, Ghrelin, LEAP2, Adiponectin
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Systemic biomarkers of inflammation
Description
sCD163, hsCRP, IL-1, IL-1Rap IL-6, TNF-α, SAA1, SAA2, ORM1, ORM2
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Systemic biomarkers of oxidation
Description
Malonyldialdehyde and F2-Isoprostanes
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Immunometabolic profile of subcutaneous adipose tissue
Description
Pro-inflammatory (e.g. IL-6, IL1b, MCP-1, resistin, leptin, chemerin, etc.) and anti-inflammatory (e.g. adiponectin) adipocytokines.
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
RNA sequencing on subcutaneous adipose tissue
Description
Illumina sequencing
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Food preferences
Description
Leeds Food Preference Questionnaire (LFPQ)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Biometric responses to food items
Description
Eye tracking and galvanic skin response (iMotion Software)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Subjective appetite sensation
Description
Electronic visual analogue scales (VAS)
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Genetic risk score correlated to treatment response
Description
From blood samples, DNA material will be extracted and analyzed using the Infinium Global Screening Array and Illumina Genome Studio
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Gut microbiota composition
Description
Collection of saliva and fecal samples and extraction of genomic DNA
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Metabolomics in urine
Description
Urine samples
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Metabolomics in plasma
Description
Metabolomics technique
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)
Title
Proteomics in plasma
Description
Proteomics technique
Time Frame
Baseline comparison and change from baseline to end-of-treatment (68 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
28 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18-28 years The period from the initial treatment with TCOC protocol until inclusion in the study must be within 10 years. Group A: BMI>30. Non-responders: No BMI SDS reduction (<0.1 BMI SDS) during TCOC protocol for more than one year and still have obesity (BMI>30). Group B: BMI>30. Insufficient responders: BMI SDS reduction >0.25 BMI SDS during TCOC protocol for more than one year, but still have obesity (BMI>30). Only baseline examination: Group C: BMI<30. Excellent responders: BMI SDS reduction >0.5 BMI SDS during TCOC protocol for more than one year and no longer have obesity (BMI<30). Exclusion Criteria: Participants diagnosed with known serious chronic illness including type 1 or 2 diabetes (or a randomly measured fasting plasma glucose > 7 mmol/l) Angina pectoris, coronary heart disease, congestive heart failure (NYHA III-IV) Severe renal impairment (creatinine clearance (GFR) <30 mL/min) Severe hepatic impairment Inflammatory bowel disease Diabetic gastroparesis Cancer Chronic obstructive lung disease Psychiatric disease, a history of major depressive or other severe psychiatric disorders Use of medications causing clinically significant weight gain or loss Previous bariatric surgery A history of idiopathic acute pancreatitis A family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma Pregnancy, expecting pregnancy or breastfeeding. If a study participant is in doubt whether she could be pregnant, a urine pregnancy test is performed. Women with reproductive potential who are not using adequate contraceptive methods (combined oral contraceptive pill, progestin-only contraceptive pill, condoms, intrauterine device, injection, implant, or sterilization). Adequate contraception must be used throughout the study period and at least 2 months after discontinuation of trial medication (semaglutide will be present in the circulation for 5-7 weeks after the last dose). Allergy to any of the ingredients/excipients of the study medication: Semaglutide, disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid, sodium hydroxide.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Signe S Torekov, Prof, PhD
Phone
+4535327509
Ext
+4522983827
Email
torekov@sund.ku.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Sarah Byberg, MD, PhD
Phone
+4550247452
Email
sarah.byberg@sund.ku.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Signe S Torekov, Prof, PhD
Organizational Affiliation
University of Copenhagen
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jens-Christian Holm, Ass. Prof, PhD
Organizational Affiliation
Holbæk University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Holbæk University Hospital
City
Holbæk
State/Province
Region Zeeland
ZIP/Postal Code
4300
Country
Denmark
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jens-Christian Holm, Ass. Prof, PhD
Phone
+4526207533
Email
jhom@regionsjaelland.dk
Facility Name
University of Copenhagen, Department of Biomedical Sciences
City
Copenhagen
ZIP/Postal Code
2200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Signe S Torekov
Phone
+4535327509 / +4522983827
Email
torekov@sund.ku.dk
First Name & Middle Initial & Last Name & Degree
Sarah Byberg
Phone
+4550247452
Email
sarah.byberg@sund.ku.dk

12. IPD Sharing Statement

Citations:
PubMed Identifier
28604169
Citation
GBD 2015 Obesity Collaborators; Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, Marczak L, Mokdad AH, Moradi-Lakeh M, Naghavi M, Salama JS, Vos T, Abate KH, Abbafati C, Ahmed MB, Al-Aly Z, Alkerwi A, Al-Raddadi R, Amare AT, Amberbir A, Amegah AK, Amini E, Amrock SM, Anjana RM, Arnlov J, Asayesh H, Banerjee A, Barac A, Baye E, Bennett DA, Beyene AS, Biadgilign S, Biryukov S, Bjertness E, Boneya DJ, Campos-Nonato I, Carrero JJ, Cecilio P, Cercy K, Ciobanu LG, Cornaby L, Damtew SA, Dandona L, Dandona R, Dharmaratne SD, Duncan BB, Eshrati B, Esteghamati A, Feigin VL, Fernandes JC, Furst T, Gebrehiwot TT, Gold A, Gona PN, Goto A, Habtewold TD, Hadush KT, Hafezi-Nejad N, Hay SI, Horino M, Islami F, Kamal R, Kasaeian A, Katikireddi SV, Kengne AP, Kesavachandran CN, Khader YS, Khang YH, Khubchandani J, Kim D, Kim YJ, Kinfu Y, Kosen S, Ku T, Defo BK, Kumar GA, Larson HJ, Leinsalu M, Liang X, Lim SS, Liu P, Lopez AD, Lozano R, Majeed A, Malekzadeh R, Malta DC, Mazidi M, McAlinden C, McGarvey ST, Mengistu DT, Mensah GA, Mensink GBM, Mezgebe HB, Mirrakhimov EM, Mueller UO, Noubiap JJ, Obermeyer CM, Ogbo FA, Owolabi MO, Patton GC, Pourmalek F, Qorbani M, Rafay A, Rai RK, Ranabhat CL, Reinig N, Safiri S, Salomon JA, Sanabria JR, Santos IS, Sartorius B, Sawhney M, Schmidhuber J, Schutte AE, Schmidt MI, Sepanlou SG, Shamsizadeh M, Sheikhbahaei S, Shin MJ, Shiri R, Shiue I, Roba HS, Silva DAS, Silverberg JI, Singh JA, Stranges S, Swaminathan S, Tabares-Seisdedos R, Tadese F, Tedla BA, Tegegne BS, Terkawi AS, Thakur JS, Tonelli M, Topor-Madry R, Tyrovolas S, Ukwaja KN, Uthman OA, Vaezghasemi M, Vasankari T, Vlassov VV, Vollset SE, Weiderpass E, Werdecker A, Wesana J, Westerman R, Yano Y, Yonemoto N, Yonga G, Zaidi Z, Zenebe ZM, Zipkin B, Murray CJL. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017 Jul 6;377(1):13-27. doi: 10.1056/NEJMoa1614362. Epub 2017 Jun 12.
Results Reference
background
PubMed Identifier
29617589
Citation
Bjerregaard LG, Jensen BW, Angquist L, Osler M, Sorensen TIA, Baker JL. Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes. N Engl J Med. 2018 Apr 5;378(14):1302-1312. doi: 10.1056/NEJMoa1713231.
Results Reference
background
PubMed Identifier
21063014
Citation
The NS, Suchindran C, North KE, Popkin BM, Gordon-Larsen P. Association of adolescent obesity with risk of severe obesity in adulthood. JAMA. 2010 Nov 10;304(18):2042-7. doi: 10.1001/jama.2010.1635.
Results Reference
background
PubMed Identifier
27423262
Citation
Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R, Jackson ChL, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda RJ, McLerran DF, Moore SC, O'Keeffe LM, Paige E, Ramond A, Reeves GK, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Zh, Gapstur SM, Gunter MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, Danesh J, Hu FB. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016 Aug 20;388(10046):776-86. doi: 10.1016/S0140-6736(16)30175-1. Epub 2016 Jul 13.
Results Reference
background
PubMed Identifier
28738325
Citation
Hebebrand J, Holm JC, Woodward E, Baker JL, Blaak E, Durrer Schutz D, Farpour-Lambert NJ, Fruhbeck G, Halford JGC, Lissner L, Micic D, Mullerova D, Roman G, Schindler K, Toplak H, Visscher TLS, Yumuk V. A Proposal of the European Association for the Study of Obesity to Improve the ICD-11 Diagnostic Criteria for Obesity Based on the Three Dimensions Etiology, Degree of Adiposity and Health Risk. Obes Facts. 2017;10(4):284-307. doi: 10.1159/000479208. Epub 2017 Jul 22.
Results Reference
background
PubMed Identifier
28264043
Citation
Mollerup PM, Gamborg M, Trier C, Bojsoe C, Nielsen TR, Baker JL, Holm JC. A hospital-based child and adolescent overweight and obesity treatment protocol transferred into a community healthcare setting. PLoS One. 2017 Mar 6;12(3):e0173033. doi: 10.1371/journal.pone.0173033. eCollection 2017.
Results Reference
background
PubMed Identifier
23181919
Citation
Nielsen TR, Gamborg M, Fonvig CE, Kloppenborg J, Hvidt KN, Ibsen H, Holm JC. Changes in lipidemia during chronic care treatment of childhood obesity. Child Obes. 2012 Dec;8(6):533-41. doi: 10.1089/chi.2011.0098.
Results Reference
background
PubMed Identifier
24733029
Citation
Hvidt KN, Olsen MH, Ibsen H, Holm JC. Effect of changes in BMI and waist circumference on ambulatory blood pressure in obese children and adolescents. J Hypertens. 2014 Jul;32(7):1470-7; discussion 1477. doi: 10.1097/HJH.0000000000000188.
Results Reference
background
PubMed Identifier
26714769
Citation
Fonvig CE, Chabanova E, Ohrt JD, Nielsen LA, Pedersen O, Hansen T, Thomsen HS, Holm JC. Multidisciplinary care of obese children and adolescents for one year reduces ectopic fat content in liver and skeletal muscle. BMC Pediatr. 2015 Dec 30;15:196. doi: 10.1186/s12887-015-0513-6.
Results Reference
background
PubMed Identifier
24251641
Citation
Torekov SS, Holst JJ, Ehlers MR. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014 May;16(5):451-6. doi: 10.1111/dom.12240. Epub 2013 Dec 10.
Results Reference
background
PubMed Identifier
21362122
Citation
Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab. 2011 Jul;13(7):639-43. doi: 10.1111/j.1463-1326.2011.01388.x.
Results Reference
background
PubMed Identifier
21401851
Citation
Torekov SS, Madsbad S, Holst JJ. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential. Obes Rev. 2011 Aug;12(8):593-601. doi: 10.1111/j.1467-789X.2011.00860.x. Epub 2011 Mar 15.
Results Reference
background
PubMed Identifier
9449682
Citation
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. doi: 10.1172/JCI990.
Results Reference
background
PubMed Identifier
25677912
Citation
Faerch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, Pedersen O, Hansen T, Lauritzen T, Sandbaek A, Holst JJ, Jorgensen ME. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes. 2015 Jul;64(7):2513-25. doi: 10.2337/db14-1751. Epub 2015 Feb 12.
Results Reference
background
PubMed Identifier
26976129
Citation
Iepsen EW, Lundgren J, Holst JJ, Madsbad S, Torekov SS. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36. Eur J Endocrinol. 2016 Jun;174(6):775-84. doi: 10.1530/EJE-15-1116. Epub 2016 Mar 14.
Results Reference
background
PubMed Identifier
25287751
Citation
Iepsen EW, Lundgren J, Dirksen C, Jensen JE, Pedersen O, Hansen T, Madsbad S, Holst JJ, Torekov SS. Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss. Int J Obes (Lond). 2015 May;39(5):834-41. doi: 10.1038/ijo.2014.177. Epub 2014 Oct 7.
Results Reference
background
PubMed Identifier
33951361
Citation
Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, Svane MS, Bandholm T, Bojsen-Moller KN, Blond MB, Jensen JB, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198.
Results Reference
background
PubMed Identifier
29207396
Citation
Christensen BJ, Iepsen EW, Lundgren J, Holm L, Madsbad S, Holst JJ, Torekov SS. Instrumentalization of Eating Improves Weight Loss Maintenance in Obesity. Obes Facts. 2017;10(6):633-647. doi: 10.1159/000481138. Epub 2017 Dec 6.
Results Reference
background
PubMed Identifier
35970829
Citation
Jensen SBK, Janus C, Lundgren JR, Juhl CR, Sandsdal RM, Olsen LM, Andresen A, Borg SA, Jacobsen IC, Finlayson G, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment. Nat Commun. 2022 Aug 15;13(1):4770. doi: 10.1038/s41467-022-32307-y.
Results Reference
background
PubMed Identifier
32921795
Citation
Trier C, Hollensted M, Schnurr TM, Lund MAV, Nielsen TRH, Rui G, Andersson EA, Svendstrup M, Bille DS, Gjesing AP, Fonvig CE, Frithioff-Bojsoe C, Balslev-Harder M, Quan S, Gamborg M, Pedersen O, Angquist L, Holm JC, Hansen T. Obesity treatment effect in Danish children and adolescents carrying Melanocortin-4 Receptor mutations. Int J Obes (Lond). 2021 Jan;45(1):66-76. doi: 10.1038/s41366-020-00673-6. Epub 2020 Sep 13.
Results Reference
background
PubMed Identifier
27222505
Citation
Bonnefond A, Keller R, Meyre D, Stutzmann F, Thuillier D, Stefanov DG, Froguel P, Horber FF, Kral JG. Eating Behavior, Low-Frequency Functional Mutations in the Melanocortin-4 Receptor (MC4R) Gene, and Outcomes of Bariatric Operations: A 6-Year Prospective Study. Diabetes Care. 2016 Aug;39(8):1384-92. doi: 10.2337/dc16-0115. Epub 2016 May 23.
Results Reference
background
PubMed Identifier
29861388
Citation
Iepsen EW, Zhang J, Thomsen HS, Hansen EL, Hollensted M, Madsbad S, Hansen T, Holst JJ, Holm JC, Torekov SS. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist. Cell Metab. 2018 Jul 3;28(1):23-32.e3. doi: 10.1016/j.cmet.2018.05.008. Epub 2018 May 31.
Results Reference
background
PubMed Identifier
35015037
Citation
Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sorrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.
Results Reference
background

Learn more about this trial

Young Adults With Early-onset Obesity Treated With Semaglutide

We'll reach out to this number within 24 hrs